出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年7月
分子品質管理市場 : 製品 [独立制御、機器固有のコントロール (PCR、DNA シーケンス)、用途 (感染症診断)]、検体の種類、エンドユーザー (病院、診断研究所)、地域別 – 2028年までの世界予測
Molecular Quality Controls Market Product (Independent Control, Instrument Specific Control (PCR, DNA Sequencing), Application (Infectious Disease Diagnostics), Analyte type, End User (Hospitals, Diagnostic Lab), Region- Global Forecast to 2028
| ページ数 | 282 |
| 図表数 | 249 |
| 種別 | 英文調査報告書 |
| 価格 |
The global molecular quality controls market is projected to reach USD 0.3 billion by 2028 from USD 0.2 billion in 2023, at a CAGR of 6.6% during the forecast period. Growth in this market is primarily driven by the increasing government funding for genomic projects, increasing demand for personalized medicines and declining costs of sequencing procedures, and increasing prevalence of infectious diseases, cancer, and genetic diseases.
However, the additional costs involved in the quality control process and budget constraints in hospitals and laboratories, and the unfavorable reimbursement scenario for molecular tests are the major factors that are expected to restrain the growth of this market during the forecast period.
The independent controls segment has accounted for the biggest share of the market during the forecast period
By product, the molecular quality controls market is segmented into independent controls and instrument-specific controls. The independent controls segment accounted for the biggest share of the global molecular quality controls market in 2022. The increasing use of third-party independent quality controls is responsible for the large share of this segment.
The single-analyte controls has accounted for the biggest share of the market during the forecast period.
By analyte type, the molecular quality controls market is divided into single-analyte controls and multi-analyte controls. Single-analyte controls accounted for the biggest share of the molecular quality controls market in 2022. Factors such as the significant use of singleplex assays in hospitals, and low risk of cross-reactivity are responsible for the large share of this segment.
The infectious disease diagnostic segment accounted for the biggest share of the market in 2022
By application, the molecular quality controls market is divided into infectious disease diagnostics, genetic testing, oncology testing, and other applications (including neurology disease testing, , DNA fingerprinting, tissue typing, microbiology and cardiovascular disease testing). The infectious disease diagnostics segment accounted for the biggest share of the global molecular quality controls market in 2022. The significant increase in the prevalence of infectious diseases is responsible for the large share of this segment.
The diagnostic laboratories segment accounted for the biggest share of the market in 2022
By end users, the molecular quality controls market is segmented into academic & research institutes, diagnostic laboratories, IVD manufacturers & CROs, hospitals and other end users (home health agencies, blood banks, nursing homes, and local public health laboratories). The diagnostic laboratories segment accounted for the biggest share of the molecular quality controls market in 2022. The growing number of laboratory tests performed in diagnostic laboratories is responsible for the large share of this segment.
North America accounted for the largest share of the Molecular Quality Controls market in 2022
Based on region, the molecular quality controls market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the molecular quality controls market in 2022. The large share of this regional segment is mainly due to the developed healthcare system in the US and Canada, the presence of many leading molecular quality control product manufacturers, and easy accessibility to technologically advanced products in North America.
The break up of the profile of primary participants in the molecular Quality controls market:
• By Company Type: Tier 1- 35%, Tier 2- 45%, and Tier 3-20%
• By Designation: C-level Executives- 35%, Directors- 25% , and Others- 40%.
• By Region: North America – 40%, Europe – 30%, APAC –20%, Latin America – 5%,Middle East & Africa–5%
Key players in the molecular quality controls market
The key players operating in the molecular quality controls market include Microbiologics, Inc. (US), Steck, Inc. (US), Bio-Rad Laboratories, Inc. (US), Anchor Molecular (US), Thermo Fisher Scientific, Inc. (US), Randox Laboratories Ltd. (UK), LGC Limited (UK), Abbott Laboratories (US), Fortress Diagnostics (UK), SERO AS (Norway), Anchor Molecular (US), Vircell S.L. (Spain), Ortho Clinical Diagnostics, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Microbix Biosystems Inc. (Canada), Molbio Diagnostics Pvt. Ltd. (India), QuidelOrthoCorporation (US), Sun Diagnostics, LLC (US), Seegene Inc. (South Korea), ZeptoMetrix, LLC (US), Qnostics (UK), Bio-Techne Corporation (US), Helena Laboratories Corporation (US), SpeeDx Pty. Ltd. (Australia), Maine Molecular Quality Controls, Inc. (US), and Grifols, S.A. (Spain).
Research Coverage:
The report analyzes the molecular quality controls market and aims at estimating the market size and future growth potential of this market based on various segments such as product, analyte type, application, and end user. The report also includes a product portfolio matrix of various molecular quality controls products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, service offerings, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.
This report provides insights into the following pointers:
• Analysis of key drivers (growing adoption of third-party quality controls, increasing investments in genomics, growing preference for personalized medicines, rising demand for external quality assessment support, and increasing prevalence of infectious diseases and cancer), restraints (high costs and budget constraints in clinical laboratories, and unfavorable reimbursement for molecular tests), opportunities (rising demand for multi-analyte controls, and growth opportunities in emerging countries), and challenges (changing regulatory framework)
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new product launches in the global molecular quality controls market
• Market Development: Comprehensive information on the lucrative emerging markets by product, analyte type, application, and end user.
• Market Diversification: Exhaustive information about new services or service enhancements, growing geographies, recent developments, and investments in the global molecular quality controls market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global molecular quality controls market. This report also helps stakeholders understand the pulse of the molecular quality controls market and provides them information on key market drivers, restraints, challenges, and opportunities.
目次
1 INTRODUCTION 24
1.1 STUDY OBJECTIVES 24
1.2 MARKET DEFINITION 24
1.2.1 INCLUSIONS AND EXCLUSIONS 24
1.3 MARKET SCOPE 25
1.3.1 MARKETS COVERED 25
1.3.2 YEARS CONSIDERED 26
1.4 CURRENCY CONSIDERED 26
TABLE 1 STANDARD CURRENCY CONVERSION RATES 26
1.5 STUDY LIMITATIONS 27
1.6 STAKEHOLDERS 27
1.7 SUMMARY OF CHANGES 27
1.8 RECESSION IMPACT 28
2 RESEARCH METHODOLOGY 29
2.1 RESEARCH DATA 29
FIGURE 1 RESEARCH DESIGN 29
2.2 RESEARCH DESIGN 29
2.2.1 SECONDARY RESEARCH 29
2.2.1.1 Key data from secondary sources 30
2.2.2 PRIMARY RESEARCH 31
FIGURE 2 PRIMARY SOURCES 31
2.2.2.1 Key data from primary sources 32
FIGURE 3 INSIGHTS FROM INDUSTRY EXPERTS 33
2.2.2.2 Breakdown of primaries 33
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 33
2.3 MARKET SIZE ESTIMATION 34
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 35
FIGURE 6 MOLECULAR QUALITY CONTROLS MARKET: REVENUE SHARE ANALYSIS 36
FIGURE 7 MARKET SIZE ESTIMATION: PARENT MARKET 37
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 38
FIGURE 9 MOLECULAR QUALITY CONTROLS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 39
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 41
FIGURE 10 DATA TRIANGULATION METHODOLOGY 41
2.5 MARKET SHARE ANALYSIS 42
2.6 STUDY ASSUMPTIONS 42
2.7 RISK ASSESSMENT 42
TABLE 2 MOLECULAR QUALITY CONTROLS MARKET: RISK ASSESSMENT ANALYSIS 42
2.8 MARKET LIMITATIONS 43
2.8.1 METHODOLOGY-RELATED LIMITATIONS 43
2.8.2 SCOPE-RELATED LIMITATIONS 43
2.9 RECESSION IMPACT ANALYSIS 43
3 EXECUTIVE SUMMARY 45
FIGURE 11 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 45
FIGURE 12 MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2023 VS. 2028 (USD MILLION) 46
FIGURE 13 MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 46
FIGURE 14 MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 47
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF MOLECULAR QUALITY CONTROLS MARKET 48
4 PREMIUM INSIGHTS 49
4.1 MOLECULAR QUALITY CONTROLS MARKET OVERVIEW 49
FIGURE 16 RISING PREVALENCE OF INFECTIOUS DISEASES AND CANCER TO DRIVE MARKET 49
4.2 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT 50
FIGURE 17 INSTRUMENT-SPECIFIC CONTROLS SEGMENT TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 50
4.3 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION AND COUNTRY 51
FIGURE 18 INFECTIOUS DISEASE DIAGNOSTICS SEGMENT IN JAPAN ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 51
4.4 MOLECULAR QUALITY CONTROLS MARKET: GEOGRAPHICAL MIX 52
FIGURE 19 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 52
4.5 MOLECULAR QUALITY CONTROLS MARKET: DEVELOPED MARKETS VS. EMERGING MARKETS 53
FIGURE 20 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
FIGURE 21 MOLECULAR QUALITY CONTROLS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54
5.1.1 DRIVERS 55
5.1.1.1 Rising number of accredited clinical laboratories 55
FIGURE 22 NUMBER OF LABORATORIES WITH CLIA ACCREDITATION, BY ORGANIZATION (MAY 2023) 55
5.1.1.2 Growing adoption of third-party quality controls 56
TABLE 3 THIRD-PARTY INDEPENDENT QUALITY CONTROLS OFFERED BY KEY COMPANIES 56
5.1.1.3 Increasing investments in genomics 57
TABLE 4 GOVERNMENT FUNDING INITIATIVES FOR GENOMICS RESEARCH (2019−2022) 57
5.1.1.4 Growing preference for personalized medicine 58
TABLE 5 US: NUMBER OF PERSONALIZED MEDICINES AVAILABLE (2008–2020) 59
FIGURE 23 FDA-APPROVED PERSONALIZED MEDICINES (2015–2022) 59
FIGURE 24 COST OF SEQUENCING PROCEDURES (2016−2021) 60
5.1.1.5 Increasing prevalence of infectious diseases and cancer 60
FIGURE 25 GLOBAL CANCER INCIDENCE, 2018–2040 (MILLION) 61
5.1.1.6 Rising demand for external quality assessment support 62
5.1.2 RESTRAINTS 62
5.1.2.1 Budgetary constraints in clinical laboratories 62
5.1.2.2 Unfavorable reimbursements for molecular tests 63
5.1.3 OPPORTUNITIES 63
5.1.3.1 Rising demand for multi-analyte controls 63
5.1.3.2 Growth opportunities in emerging markets 64
5.1.4 CHALLENGES 64
5.1.4.1 Stringent regulatory requirements for IVD products 64
5.2 INDUSTRY TRENDS 65
5.2.1 LYOPHILIZED/FREEZE-DRIED CONTROLS 65
TABLE 6 LYOPHILIZED OR FREEZE-DRIED QUALITY CONTROLS OFFERED BY KEY COMPANIES 65
5.3 PRICING ANALYSIS 66
TABLE 7 PRICE RANGE FOR MOLECULAR QUALITY CONTROLS, BY TYPE (2022) 66
5.4 VALUE CHAIN ANALYSIS 66
FIGURE 26 VALUE CHAIN ANALYSIS 67
5.5 SUPPLY CHAIN ANALYSIS 67
FIGURE 27 SUPPLY CHAIN ANALYSIS 68
5.6 ECOSYSTEM ANALYSIS 68
FIGURE 28 MOLECULAR QUALITY CONTROLS MARKET: ECOSYSTEM MARKET MAP 69
5.7 PORTER’S FIVE FORCES ANALYSIS 69
TABLE 8 MOLECULAR QUALITY CONTROLS MARKET: PORTER’S FIVE FORCES ANALYSIS 69
5.7.1 THREAT OF NEW ENTRANTS 70
5.7.2 THREAT OF SUBSTITUTES 70
5.7.3 BARGAINING POWER OF BUYERS 70
5.7.4 BARGAINING POWER OF SUPPLIERS 70
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 71
5.8 TRADE ANALYSIS 71
5.8.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS 71
5.8.1.1 Import data for diagnostic & laboratory reagents, by country, 2018–2021 (USD million) 71
5.8.1.2 Export data for diagnostic & laboratory reagents, by country, 2018–2021 (USD million) 71
5.9 TARIFF AND REGULATORY ANALYSIS 72
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72
TABLE 9 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72
5.9.2 REGULATORY ANALYSIS 72
5.9.2.1 North America 72
5.9.2.1.1 US 72
TABLE 10 US FDA: MEDICAL DEVICE CLASSIFICATION 73
TABLE 11 US: CLASSIFICATION OF QUALITY CONTROL MATERIAL 73
TABLE 12 US: CLASSIFICATION, TIME, AND COMPLEXITY OF REGISTRATION 73
5.9.2.1.2 Canada 74
TABLE 13 CANADA: CLASSIFICATION OF IVD PRODUCTS 74
TABLE 14 CANADA: CLASSIFICATION, TIME, AND COMPLEXITY OF REGISTRATION 74
5.9.2.2 Europe 75
TABLE 15 EUROPE: ACCREDITATION BODIES FOR MEDICAL LABORATORIES 75
5.9.2.3 Asia Pacific 75
5.9.2.3.1 Japan 75
5.9.2.3.2 China 76
5.9.2.3.3 India 76
5.10 PATENT ANALYSIS 76
5.10.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 76
FIGURE 29 MOLECULAR QUALITY CONTROLS MARKET: TOP PATENT OWNERS AND APPLICANTS (JANUARY 2011–JUNE 2023) 77
FIGURE 30 MOLECULAR QUALITY CONTROLS MARKET: TOP APPLICANT JURISDICTIONS (JANUARY 2011–JUNE 2023) 78
5.10.2 PATENT PUBLICATION TRENDS 78
FIGURE 31 MOLECULAR QUALITY CONTROLS MARKET: PATENT ANALYSIS (JANUARY 2011–FEBRUARY 2023) 78
TABLE 16 MOLECULAR QUALITY CONTROLS MARKET: LIST OF PATENTS/PATENT APPLICATIONS (2020–2023) 79
5.11 KEY CONFERENCES AND EVENTS 80
TABLE 17 MOLECULAR QUALITY CONTROLS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2023–2024 80
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 81
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 81
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MOLECULAR QUALITY CONTROL PRODUCTS 81
TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MOLECULAR QUALITY CONTROL PRODUCTS (%) 81
5.12.2 BUYING CRITERIA 82
FIGURE 33 KEY BUYING CRITERIA FOR MOLECULAR QUALITY CONTROL PRODUCTS 82
TABLE 19 KEY BUYING CRITERIA FOR MOLECULAR QUALITY CONTROL PRODUCTS 82
5.13 TRENDS AND DISRUPTIONS AFFECTING CUSTOMERS’ BUSINESSES 83
FIGURE 34 MOLECULAR QUALITY CONTROLS MARKET: REVENUE SHIFT 83
6 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT 84
6.1 INTRODUCTION 85
TABLE 20 QUALITY CONTROLS FOR MOLECULAR DIAGNOSTICS OFFERED BY KEY MARKET PLAYERS 85
TABLE 21 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 86
6.2 INDEPENDENT CONTROLS 86
6.2.1 MINIMIZED LOT CROSSOVERS FOR LABORATORIES AND LOW OPERATION COSTS TO DRIVE MARKET 86
TABLE 22 INDEPENDENT MOLECULAR QUALITY CONTROLS OFFERED BY KEY MARKET PLAYERS 86
TABLE 23 INDEPENDENT MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87
6.3 INSTRUMENT-SPECIFIC CONTROLS 88
TABLE 24 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS OFFERED BY KEY MARKET PLAYERS 88
TABLE 25 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 26 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 89
6.3.1 POLYMERASE CHAIN REACTION 90
6.3.1.1 Rising applications in proteomics and genomics to propel market 90
TABLE 27 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS MARKET FOR PCR, BY COUNTRY, 2021–2028 (USD MILLION) 91
6.3.2 DNA SEQUENCING AND NGS 91
6.3.2.1 Increasing advancements in sequencing technologies to drive market 91
TABLE 28 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2021–2028 (USD MILLION) 92
6.3.3 OTHER TECHNOLOGIES 92
TABLE 29 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION) 93
7 MOLECULAR QUALITY CONTROL MARKET, BY ANALYTE TYPE 94
7.1 INTRODUCTION 95
TABLE 30 MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 95
7.2 SINGLE-ANALYTE CONTROLS 95
7.2.1 RISING ADOPTION OF SINGLEPLEX ASSAYS IN HOSPITALS TO SUPPORT MARKET GROWTH 95
TABLE 31 SINGLE-ANALYTE CONTROLS OFFERED BY KEY MARKET PLAYERS 96
TABLE 32 SINGLE-ANALYTE MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 96
7.3 MULTI-ANALYTE CONTROLS 97
7.3.1 GROWING PREFERENCE FOR COST-EFFECTIVE CONTROLS TO DRIVE MARKET 97
TABLE 33 MULTI-ANALYTE CONTROLS OFFERED BY KEY MARKET PLAYERS 97
TABLE 34 MULTI-ANALYTE MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 98
8 MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION 99
8.1 INTRODUCTION 100
TABLE 35 MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 100
8.2 INFECTIOUS DISEASE DIAGNOSTICS 100
8.2.1 RISING INCIDENCE OF INFLUENZA, TB, AND HIV TO DRIVE MARKET 100
TABLE 36 NUMBER OF COVID-19 CASES, BY COUNTRY (FEBRUARY 2023) 101
TABLE 37 MOLECULAR QUALITY CONTROLS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 102
8.3 ONCOLOGY TESTING 103
8.3.1 GROWING FOCUS ON PERSONALIZED MEDICINE TO PROPEL MARKET 103
TABLE 38 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 104
TABLE 39 MOLECULAR QUALITY CONTROLS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2021–2028 (USD MILLION) 105
8.4 GENETIC TESTING 105
8.4.1 ABILITY TO DIAGNOSE RARE DISEASES TO SUPPORT MARKET GROWTH 105
TABLE 40 MOLECULAR QUALITY CONTROLS MARKET FOR GENETIC TESTING, BY COUNTRY, 2021–2028 (USD MILLION) 106
8.5 OTHER APPLICATIONS 106
TABLE 41 MOLECULAR QUALITY CONTROLS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 107
9 MOLECULAR QUALITY CONTROLS MARKET, BY END USER 108
9.1 INTRODUCTION 109
TABLE 42 MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 109
9.2 DIAGNOSTIC LABORATORIES 109
9.2.1 INCREASING NUMBER OF ACCREDITED DIAGNOSTIC LABORATORIES TO DRIVE MARKET 109
TABLE 43 MOLECULAR QUALITY CONTROLS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 111
9.3 HOSPITALS 111
9.3.1 ABILITY TO CONDUCT LARGE VOLUME OF DIAGNOSTIC PROCEDURES TO PROPEL MARKET 111
TABLE 44 MOLECULAR QUALITY CONTROLS MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION) 113
9.4 IVD MANUFACTURERS AND CONTRACT RESEARCH ORGANIZATIONS 113
9.4.1 ADVANCEMENTS IN MOLECULAR TECHNOLOGIES TO SUPPORT MARKET GROWTH 113
TABLE 45 MOLECULAR QUALITY CONTROLS MARKET FOR IVD MANUFACTURERS AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 114
9.5 ACADEMIC & RESEARCH INSTITUTES 114
9.5.1 RISING FOCUS ON ACCURATE RESEARCH RESULTS TO DRIVE MARKET 114
TABLE 46 MOLECULAR QUALITY CONTROLS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 115
9.6 OTHER END USERS 115
TABLE 47 MOLECULAR QUALITY CONTROLS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 116
10 MOLECULAR QUALITY CONTROLS MARKET, BY REGION 117
10.1 INTRODUCTION 118
TABLE 48 MOLECULAR QUALITY CONTROLS MARKET, BY REGION, 2021–2028 (USD MILLION) 118
10.2 NORTH AMERICA 118
FIGURE 35 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET SNAPSHOT 119
TABLE 49 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 50 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 120
TABLE 51 NORTH AMERICA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 120
TABLE 52 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 120
TABLE 53 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 121
TABLE 54 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 121
10.2.1 US 121
10.2.1.1 Growing number of accredited clinical laboratories to drive market 121
FIGURE 36 US: NUMBER OF LABORATORIES WITH CLIA ACCREDITATION, BY ORGANIZATION (MAY 2023) 122
TABLE 55 US: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 123
TABLE 56 US: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 123
TABLE 57 US: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 123
TABLE 58 US: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 124
TABLE 59 US: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 124
10.2.2 CANADA 124
10.2.2.1 Rising funding investments for genomic research to propel market 124
TABLE 60 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 125
TABLE 61 CANADA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 126
TABLE 62 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 126
TABLE 63 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 126
TABLE 64 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 127
10.2.3 NORTH AMERICA: RECESSION IMPACT 127
10.3 EUROPE 127
TABLE 65 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 66 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 128
TABLE 67 EUROPE: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 129
TABLE 68 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 129
TABLE 69 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 129
TABLE 70 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 130
10.3.1 GERMANY 130
10.3.1.1 Rising volume of diagnostic tests in clinical settings to drive market 130
TABLE 71 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 130
TABLE 72 GERMANY: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 131
TABLE 73 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 131
TABLE 74 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 131
TABLE 75 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 132
10.3.2 UK 132
10.3.2.1 Growth in life sciences industry to propel market 132
TABLE 76 UK: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 133
TABLE 77 UK: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 133
TABLE 78 UK: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 133
TABLE 79 UK: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 134
TABLE 80 UK: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 134
10.3.3 FRANCE 134
10.3.3.1 Rising prevalence of cancer and endocrine disorders to support market growth 134
TABLE 81 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 135
TABLE 82 FRANCE: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 135
TABLE 83 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 135
TABLE 84 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 136
TABLE 85 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 136
10.3.4 ITALY 136
10.3.4.1 Rising incidence of age-associated chronic ailments to support market growth 136
TABLE 86 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 137
TABLE 87 ITALY: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 137
TABLE 88 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 137
TABLE 89 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 138
TABLE 90 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 138
10.3.5 SPAIN 138
10.3.5.1 Increasing demand for prenatal and genetic testing to support market growth 138
TABLE 91 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 139
TABLE 92 SPAIN: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 139
TABLE 93 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 140
TABLE 94 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 140
TABLE 95 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 140
10.3.6 RUSSIA 141
10.3.6.1 Growing acceptance of molecular diagnostics-based personalized medicine to propel market 141
TABLE 96 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 141
TABLE 97 RUSSIA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 141
TABLE 98 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 142
TABLE 99 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 142
TABLE 100 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 142
10.3.7 REST OF EUROPE 143
TABLE 101 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 143
TABLE 102 REST OF EUROPE: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 143
TABLE 103 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 144
TABLE 104 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 144
TABLE 105 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 144
10.3.8 EUROPE: RECESSION IMPACT 145
10.4 ASIA PACIFIC 145
FIGURE 37 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET SNAPSHOT 146
TABLE 106 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 107 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 147
TABLE 108 ASIA PACIFIC: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 147
TABLE 109 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 148
TABLE 110 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 148
TABLE 111 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 148
10.4.1 JAPAN 149
10.4.1.1 Established healthcare system and rising demand for high-quality IVD tests to drive market 149
TABLE 112 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 149
TABLE 113 JAPAN: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 149
TABLE 114 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 150
TABLE 115 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 150
TABLE 116 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 150
10.4.2 CHINA 151
10.4.2.1 Rising R&D investments for advanced molecular tests to drive market 151
TABLE 117 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 151
TABLE 118 CHINA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 152
TABLE 119 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 152
TABLE 120 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 152
TABLE 121 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 153
10.4.3 INDIA 153
10.4.3.1 Rising need to secure NABL accreditations to support market growth 153
FIGURE 38 INDIA: INCREASING NUMBER OF LABORATORIES WITH NABL ACCREDITATIONS (2012–2020) 154
TABLE 122 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 154
TABLE 123 INDIA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 155
TABLE 124 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 155
TABLE 125 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 155
TABLE 126 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 156
10.4.4 AUSTRALIA 156
10.4.4.1 High prevalence of infectious diseases to fuel market 156
TABLE 127 AUSTRALIA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 156
TABLE 128 AUSTRALIA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 157
TABLE 129 AUSTRALIA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 157
TABLE 130 AUSTRALIA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 157
TABLE 131 AUSTRALIA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 158
10.4.5 REST OF ASIA PACIFIC 158
TABLE 132 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 158
TABLE 133 REST OF ASIA PACIFIC: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 159
TABLE 134 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 159
TABLE 135 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 159
TABLE 136 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 160
10.4.6 ASIA PACIFIC: RECESSION IMPACT 160
10.5 LATIN AMERICA 160
TABLE 137 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 138 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 161
TABLE 139 LATIN AMERICA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 161
TABLE 140 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 162
TABLE 141 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 162
TABLE 142 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, ‘ 2021–2028 (USD MILLION) 162
10.5.1 BRAZIL 163
10.5.1.1 Improving healthcare infrastructure to support market growth 163
TABLE 143 BRAZIL: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 163
TABLE 144 BRAZIL: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 163
TABLE 145 BRAZIL: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 164
TABLE 146 BRAZIL: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 164
TABLE 147 BRAZIL: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 164
10.5.2 MEXICO 165
10.5.2.1 Improving accessibility and affordability of healthcare services to support market growth 165
TABLE 148 MEXICO: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 165
TABLE 149 MEXICO: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 165
TABLE 150 MEXICO: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 166
TABLE 151 MEXICO: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 166
TABLE 152 MEXICO: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 166
10.5.3 REST OF LATIN AMERICA 167
TABLE 153 REST OF LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 167
TABLE 154 REST OF LATIN AMERICA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 167
TABLE 155 REST OF LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 167
TABLE 156 REST OF LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 168
TABLE 157 REST OF LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 168
10.5.4 LATIN AMERICA: RECESSION IMPACT 168
10.6 MIDDLE EAST & AFRICA 169
10.6.1 GOVERNMENT INITIATIVES TO IMPROVE HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH 169
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 169
TABLE 158 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 169
TABLE 159 MIDDLE EAST & AFRICA: INSTRUMENT-SPECIFIC MOLECULAR CONTROLS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 170
TABLE 160 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021–2028 (USD MILLION) 170
TABLE 161 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 170
TABLE 162 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021–2028 (USD MILLION) 171
11 COMPETITIVE LANDSCAPE 172
11.1 OVERVIEW 172
11.2 STRATEGIES ADOPTED BY KEY PLAYERS 173
11.3 REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS 174
FIGURE 39 MOLECULAR QUALITY CONTROLS MARKET: REVENUE SHARE ANALYSIS OF LEADING PLAYERS 174
11.4 MARKET SHARE ANALYSIS 175
FIGURE 40 MOLECULAR QUALITY CONTROLS MARKET SHARE ANALYSIS, BY KEY PLAYER (2022) 175
TABLE 163 MOLECULAR QUALITY CONTROLS MARKET: INTENSITY OF COMPETITIVE RIVALRY 176
11.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 177
11.5.1 STARS 177
11.5.2 EMERGING LEADERS 177
11.5.3 PERVASIVE PLAYERS 178
11.5.4 PARTICIPANTS 178
FIGURE 41 MOLECULAR QUALITY CONTROLS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 178
11.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 179
11.6.1 PROGRESSIVE COMPANIES 179
11.6.2 STARTING BLOCKS 179
11.6.3 RESPONSIVE COMPANIES 179
11.6.4 DYNAMIC COMPANIES 179
FIGURE 42 MOLECULAR QUALITY CONTROLS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 180
11.7 COMPANY FOOTPRINT ANALYSIS 180
TABLE 164 MOLECULAR QUALITY CONTROLS MARKET: COMPANY FOOTPRINT ANALYSIS 181
TABLE 165 MOLECULAR QUALITY CONTROLS MARKET: ANALYTE TYPE FOOTPRINT ANALYSIS 182
TABLE 166 MOLECULAR QUALITY CONTROLS MARKET: APPLICATION FOOTPRINT ANALYSIS 183
TABLE 167 MOLECULAR QUALITY CONTROLS MARKET: REGIONAL FOOTPRINT ANALYSIS 184
TABLE 168 MOLECULAR QUALITY CONTROLS MARKET: END USER FOOTPRINT ANALYSIS 185
11.8 COMPETITIVE SITUATION AND TRENDS 186
11.8.1 PRODUCT LAUNCHES & APPROVALS 186
TABLE 169 PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–JUNE 2023) 186
11.8.2 DEALS 187
TABLE 170 DEALS (JANUARY 2020–JUNE 2023) 187
11.8.3 OTHER DEVELOPMENTS 187
TABLE 171 OTHER DEVELOPMENTS (JANUARY 2020–JUNE 2023) 188
12 COMPANY PROFILES 189
12.1 KEY PLAYERS 189
(Business Overview, Products/Solutions/Services offered, Recent Developments, MnM View)*
12.1.1 LGC LIMITED 189
TABLE 172 LGC LIMITED: BUSINESS OVERVIEW 189
FIGURE 43 LCG LIMITED: COMPANY SNAPSHOT (2022) 190
12.1.2 THERMO FISHER SCIENTIFIC, INC. 198
TABLE 173 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 198
FIGURE 44 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022) 199
12.1.3 BIO-RAD LABORATORIES, INC. 205
TABLE 174 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 205
FIGURE 45 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 206
12.1.4 MICROBIOLOGICS, INC. 209
TABLE 175 MICROBIOLOGICS, INC.: BUSINESS OVERVIEW 209
12.1.5 ABBOTT LABORATORIES 214
TABLE 176 ABBOTT LABORATORIES: BUSINESS OVERVIEW 214
FIGURE 46 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 215
12.1.6 F. HOFFMANN-LA ROCHE LTD. 218
TABLE 177 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 218
FIGURE 47 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 219
12.1.7 ZEPTOMETRIX, LLC 221
TABLE 178 ZEPTOMETRIX, LLC: BUSINESS OVERVIEW 221
12.1.8 QUIDELORTHO CORPORATION 226
TABLE 179 QUIDELORTHO CORPORATION: BUSINESS OVERVIEW 226
FIGURE 48 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022) 227
12.1.9 QNOSTICS 229
TABLE 180 QNOSTICS: BUSINESS OVERVIEW 229
12.1.10 MAINE MOLECULAR QUALITY CONTROLS, INC. 232
TABLE 181 MAINE MOLECULAR QUALITY CONTROLS, INC.: BUSINESS OVERVIEW 232
12.1.11 RANDOX LABORATORIES LTD. 235
TABLE 182 RANDOX LABORATORIES LTD.: BUSINESS OVERVIEW 235
12.1.12 DANAHER CORPORATION 238
TABLE 183 DANAHER CORPORATION: BUSINESS OVERVIEW 238
FIGURE 49 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 239
12.1.13 BIO-TECHNE CORPORATION 241
TABLE 184 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW 241
FIGURE 50 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2022) 242
12.1.14 FORTRESS DIAGNOSTICS 244
TABLE 185 FORTRESS DIAGNOSTICS: BUSINESS OVERVIEW 244
12.1.15 MICROBIX BIOSYSTEMS 246
TABLE 186 MICROBIX BIOSYSTEMS: BUSINESS OVERVIEW 246
FIGURE 51 MICROBIX BIOSYSTEMS: COMPANY SNAPSHOT (2022) 247
12.1.16 GRIFOLS, S.A. 251
TABLE 187 GRIFOLS, S.A.: BUSINESS OVERVIEW 251
FIGURE 52 GRIFOLS, S.A.: COMPANY SNAPSHOT (2022) 252
12.1.17 ANCHOR MOLECULAR 254
TABLE 188 ANCHOR MOLECULAR: BUSINESS OVERVIEW 254
12.1.18 SPEEDX PTY. LTD. 255
TABLE 189 SPEEDX PTY. LTD.: BUSINESS OVERVIEW 255
12.1.19 SEEGENE INC. 257
TABLE 190 SEEGENE INC.: BUSINESS OVERVIEW 257
FIGURE 53 SEEGENE INC: COMPANY SNAPSHOT (2022) 258
12.1.20 HELENA LABORATORIES CORPORATION 262
TABLE 191 HELENA LABORATORIES CORPORATION: BUSINESS OVERVIEW 262
12.2 OTHER PLAYERS 265
12.2.1 SERO AS 265
TABLE 192 SERO AS: BUSINESS OVERVIEW 265
12.2.2 VIRCELL, S.L. 267
TABLE 193 VIRCELL, S.L.: BUSINESS OVERVIEW 267
12.2.3 STRECK LLC 269
TABLE 194 STRECK LLC.: BUSINESS OVERVIEW 269
12.2.4 SUN DIAGNOSTICS, LLC 271
TABLE 195 SUN DIAGNOSTICS, LLC: BUSINESS OVERVIEW 271
12.2.5 MOLBIO DIAGNOSTICS PVT. LTD. 272
TABLE 196 MOLBIO DIAGNOSTICS PVT. LTD.: BUSINESS OVERVIEW 272
*Details on Business Overview, Products/Solutions/Services offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
13 APPENDIX 273
13.1 DISCUSSION GUIDE 273
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 277
13.3 CUSTOMIZATION OPTIONS 279
13.4 RELATED REPORTS 279
13.5 AUTHOR DETAILS 280